Magle Chemoswed Holding AB
STO:MAGLE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.6
46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Magle Chemoswed Holding AB
Cost of Revenue
Magle Chemoswed Holding AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Cost of Revenue
-kr16.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Cost of Revenue
-kr6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Cost of Revenue
-kr1.1B
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Cost of Revenue
-kr794m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
|
G
|
Genovis AB
STO:GENO
|
Cost of Revenue
-kr45.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-12%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Cost of Revenue
-kr954.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-4%
|
|
Magle Chemoswed Holding AB
Glance View
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
See Also
What is Magle Chemoswed Holding AB's Cost of Revenue?
Cost of Revenue
-16.5m
SEK
Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Cost of Revenue amounts to -16.5m SEK.
What is Magle Chemoswed Holding AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-6%
Over the last year, the Cost of Revenue growth was -46%. The average annual Cost of Revenue growth rates for Magle Chemoswed Holding AB have been 18% over the past three years , -6% over the past five years .
You don't have any saved screeners yet
